Relation between non-alcoholic fatty liver disease and carotid artery intimal media thickness as a surrogate for atherosclerosis: a systematic review and meta-analysis.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
Non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis without heavy alcohol consumption or other chronic conditions, encompasses a spectrum from non-alcoholic fatty liver to non-alcoholic steatohepatitis leading to cirrhosis. This analysis aimed to investigate the correlation between NAFLD and carotid intimal media thickness (C-IMT), a non-invasive surrogate for atherosclerosis. Database searches, including PubMed, EMBASE and Cochrane Library, yielded studies up to April 2023. Included were studies exploring the NAFLD-C-IMT relationship in populations aged >18 years. Exclusions comprised non-English papers, those involving animals or pediatric populations and studies lacking control groups. No statistical significance was noted between mild and moderate NAFLD compared to the control group regarding C-IMT [95% confidence intervals (CI): -0.03, 0.12] and (95% CI: -0.03, 0.21), respectively. There was a statistically significant difference only in the Severe NAFLD group (P value 0.03). NAFLD with and without metabolic syndrome showed statistically significant differences compared to control regarding C-IMT (95% CI: 0.04, 0.12) and (95% CI: 0.01, 0.07), respectively. Fifty-nine studies were mentioned without classification of NAFLD severity and revealed a high statistically significant difference between NAFLD and controls regarding C-IMT with (95% CI: 0.09, 0.12, P < 0.00001). Stratified analysis according to sex was done in two studies and revealed statistical differences between NAFLD and control regarding C-IMT in both groups. This meta-analysis underscores a significant association between NAFLD and increased C-IMT, emphasizing the importance of assessing C-IMT in NAFLD patients to identify cardiovascular risk and tailor therapeutic interventions for improved patient outcomes.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis without heavy alcohol consumption or other chronic conditions, encompasses a spectrum from non-alcoholic fatty liver to non-alcoholic steatohepatitis leading to cirrhosis. This analysis aimed to investigate the correlation between NAFLD and carotid intimal media thickness (C-IMT), a non-invasive surrogate for atherosclerosis.
METHODOLOGY
METHODS
Database searches, including PubMed, EMBASE and Cochrane Library, yielded studies up to April 2023. Included were studies exploring the NAFLD-C-IMT relationship in populations aged >18 years. Exclusions comprised non-English papers, those involving animals or pediatric populations and studies lacking control groups.
RESULTS
RESULTS
No statistical significance was noted between mild and moderate NAFLD compared to the control group regarding C-IMT [95% confidence intervals (CI): -0.03, 0.12] and (95% CI: -0.03, 0.21), respectively. There was a statistically significant difference only in the Severe NAFLD group (P value 0.03). NAFLD with and without metabolic syndrome showed statistically significant differences compared to control regarding C-IMT (95% CI: 0.04, 0.12) and (95% CI: 0.01, 0.07), respectively. Fifty-nine studies were mentioned without classification of NAFLD severity and revealed a high statistically significant difference between NAFLD and controls regarding C-IMT with (95% CI: 0.09, 0.12, P < 0.00001). Stratified analysis according to sex was done in two studies and revealed statistical differences between NAFLD and control regarding C-IMT in both groups.
CONCLUSION
CONCLUSIONS
This meta-analysis underscores a significant association between NAFLD and increased C-IMT, emphasizing the importance of assessing C-IMT in NAFLD patients to identify cardiovascular risk and tailor therapeutic interventions for improved patient outcomes.
Identifiants
pubmed: 38489662
doi: 10.1097/MEG.0000000000002721
pii: 00042737-990000000-00319
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021; 397:2212–2224.
Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules 2022; 12:824.
Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed) 2021; 26:206–237.
Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021; 17:484–495.
Tidwell J, Balassiano N, Shaikh A, Nassar M. Emerging therapeutic options for non-alcoholic fatty liver disease: a systematic review. World J Hepatol 2023; 15:1001–1012.
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019; 92:82–97.
Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019; 71:793–801.
Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci 2021; 22. doi:10.3390/ijms22084156.
doi: 10.3390/ijms22084156
Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int 2020; 40:1254–1261.
Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158:1999–2014.e1.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78:1966–1986.
Madan SA, John F, Pyrsopoulos N, Pitchumoni CS. Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a meta-analysis. Eur J Gastroenterol Hepatol 2015; 27:1237–1248.
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019; 10:ED000142.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8:336–341.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, 2019.
Colak Y, Senates E, Yesil A, Yilmaz Y, Ozturk O, Doganay L, et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013; 43:100–107.
Hanafy AS, Seleem WM, El-Kalla F, AbdAlkhalik Basha M, Abd-Elsalam S. Efficacy of a non-invasive model in predicting the cardiovascular morbidity and histological severity in non-alcoholic fatty liver disease. Diabetes Metab Syndr 2019; 13:2272–2278.
Li X, Xia M, Ma H, Hofman A, Hu Y, Yan H, et al. Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: the Shanghai Changfeng study. Atherosclerosis 2012; 224:480–485.
Wang C, Cai Z, Deng X, Li H, Zhao Z, Guo C, et al. Association of hepatic steatosis index and fatty liver index with carotid atherosclerosis in type 2 diabetes. Int J Med Sci 2021; 18:3280–3289.
Karakurt F, Carlioglu A, Koktener A, Ozbek M, Kaya A, Uyar ME, et al. Relationship between cerebral arterial pulsatility and carotid intima media thickness in diabetic and non-diabetic patients with non-alcoholic fatty liver disease. J Endocrinol Invest 2009; 32:63–68.
Kemaloglu C, Kemaloglu MD. Non alcoholic fatty liver disease is a predictor of subclinical Carotid Atherosclerosis in the presence of Metabolic Syndrome. Nepal Heart J 2019; 16:39–45.
Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho G-Y, et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart (British Cardiac Society) 2014; 100:938–943.
Kim S-K, Choi YJ, Huh BW, Park SW, Lee EJ, Cho Y-W, et al. Nonalcoholic Fatty liver disease is associated with increased carotid intima-media thickness only in type 2 diabetic subjects with insulin resistance. J Clin Endocrinol Metab 2014; 99:1879–1884.
Nahandi MZ, Khoshbaten M, Ramazanzadeh E, Abbaszadeh L, Javadrashid R, Shirazi KM, et al. Effect of non-alcoholic fatty liver disease on carotid artery intima-media thickness as a risk factor for atherosclerosis. Gastroenterol Hepatol Bed Bench 2014; 7:55–62.
Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009; 204:521–525.
Puig J, Blasco G, Daunis-I-Estadella J, Loshuertos E, Codina J, Cuba V, et al. Nonalcoholic fatty liver disease and age are strong indicators for atherosclerosis in morbid obesity. Clin Endocrinol (Oxf) 2015; 83:180–186.
Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008; 121:72–78.
Lankarani KB, Mahmoodi M, Ghaffarpasand F, Lotfi M, Zamiri N, Heydari S, Mirzaee O, et al. Common carotid intima-media thickness in patients with NAFLD-a population-based study. J Gastroenterol Hepatol 2013; 28(SUPPL. 3):193.
Lonardo A, Lombardini S, Scaglioni F, Ballestri S, Verrone A-M, Bertolotti M, et al. Fatty liver, carotid disease and gallstones: a study of age-related associations. World J Gastroenterol 2006; 12:5826–5833.
Rampally V, Biri SK, Nair IK, Vadlakonda A. Determination of association between nonalcoholic fatty liver disease and carotid artery atherosclerosis among nondiabetic individuals. J Family Med Prim Care 2020; 9:1182–1186.
Riaz H, Iqbal J, Arif U. Association between Non-Alcoholic Fatty Liver Disease (NAFLD)& raised Carotid Intima-Media Thickness (CIMT). Pakistan J Medical Health Sci 2016; 10:1393–1396.
Zheng J, Zhou Y, Zhang K, Qi Y, An S, Wang S, et al. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old. BMC Cardiovasc Disord 2018; 18:147.
Guo YC, Zhou Y, Gao X, Yao Y, Geng B, Cui Q-H, et al. Association between nonalcoholic fatty liver disease and carotid artery disease in a community-based chinese population: a cross-sectional study. Chin Med J (Engl) 2018; 131:2269–2276.
Huang Y, Bi Y, Xu M, Ma Z, Xu Y, Wang T, et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler Thromb Vasc Biol 2012; 32:2321–2326.
Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005; 25:1045–1050.
Guo K, Zhang L, Lu J, Yu H, Wu M, Bao Y, et al. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes. J Diabetes Complications 2017; 31:80–85.
Gummesson A, Strömberg U, Schmidt C, Kullberg J, Angerås O, Lindgren S, et al. Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: a cross-sectional, population-based study in middle-aged subjects. PLoS One 2018; 13:e0202666.
Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 2016; 246:208–213.
Aygun C, Kocaman O, Sahin T, Uraz S, Eminler AT, Celebi A, et al. Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2008; 53:1352–1357.
Kang JH, Cho KI, Kim SM, Lee JY, Kim JJ, Goo JJ, et al. Relationship between Nonalcoholic Fatty Liver Disease and Carotid Artery Atherosclerosis Beyond Metabolic Disorders in Non-Diabetic Patients. J Cardiovasc Ultrasound 2012; 20:126–133.
Ayaz T, Kirbas A, Durakoglugil T, Durakoglugil ME, Sahin SB, Sahin OZ, et al. The relation between carotid intima media thickness and serum osteoprotegerin levels in nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2014; 12:283–289.
Dogru T, Genc H, Tapan S, Ercin CN, Ors F, Aslan F, et al. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes Res Clin Pract 2012; 96:47–52.
Fadaei R, Poustchi H, Meshkani R, Moradi N, Golmohammadi T, Merat S. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci Rep 2018; 8:11691.
Hanafy AS, Abd-Elsalam S, Ahmed AF, Dawoud MM. Multifocal fatty liver disease, insulin resistance and carotid atherosclerosis: exploring the interrelated relationship. J Ultrason 2018; 18:302–309.
Lankarani KB, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, Ghaffarpasand F, et al. Common carotid intima-media thickness in patients with non-alcoholic fatty liver disease: a population-based case-control study. Korean J Gastroenterol 2013; 62:344–351.
Josef P, Ali I, Ariel P, Alon M, Nimer A. Relationship between retinal vascular caliber and coronary artery disease in patients with non-alcoholic fatty liver disease (NAFLD). Int J Environ Res Public Health 2013; 10:3409–3423.
Dogan T, Ozturk K, Celikkanat S, Aykan MB, Uygun A. Comparison of anthropometric measurements for prediction of the atherosclerosis and liver histology in young adults with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2019; 31:1460–1466.
Gentili A, Daviddi G, De Vuono S, Ricci MA, Di Filippo F, Alaeddin A, et al. Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. Dig Liver Dis 2016; 48:904–908.
Genc H, Dogru T, Celebi G, Tapan S, Ercin M, Ors F, et al. Non-alcoholic fatty liver disease per se is not associated with carotid atherosclerosis. Gulhane Medical J 2013; 55:84–88.
Hong HC, Hwang SY, Ryu JY, Yoo HJ, Seo J-A, Kim SG, et al. The synergistic impact of nonalcoholic fatty liver disease and metabolic syndrome on subclinical atherosclerosis. Clin Endocrinol (Oxf) 2016; 84:203–209.
Fadaei R, Meshkani R, Poustchi H, Fallah S, Moradi N, Panahi G, et al. Association of carotid intima media thickness with atherogenic index of plasma, apo B/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease. Arch Physiol Biochem 2019; 125:19–24.
Karami S, Poustchi H, Sarmadi N, Radmard AR, Ali Yari F, Pakdel A, et al. Association of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease. Diabetol Metab Syndr 2021; 13:121.
Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009; 2:231–237.
Arinc H, Sarli B, Baktir AO, Saglam H, Demirci E, Dogan Y, et al. Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis. Ups J Med Sci 2013; 118:228–234.
Assem M, Amin M, Khalafallah O, Hussien A, Saif A, Mousa S. Hypoadiponectinemia as a marker of increased cardiovascular risk in patients with non-alcoholic fatty liver disease: correlation with albumin/creatinine ratio. Arch Endocrinol Metab 2021; 65:93–97.
Caglar GS, Kiseli M, Seker R, Ozdemir ED, Karadag D, Demirtas S. Atherogenic dyslipidemia, subclinical atherosclerosis, non-alcoholic fatty liver disease and insulin resistance in polycystic ovarian syndrome. Turk J Biochem 2015; 40:24–30.
Khalik AA, Metwaly A, Nasr FM, Al Damarawy M, Youssef A, et al. Evaluation of carotid intima- media thickness, left ventricular mass and left atrium diameter in chronic liver diseases. Life Sci J 2012; 9:1199–1206.
Kilciler G, Genc H, Tapan S, Ors F, Kara M, Karadurmus N, et al. Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease. Ups J Med Sci 2010; 115:253–259.
Kim JH, Kim SY, Jung ES, Jung SW, Koo JS, Kim JH, et al. Carotid intima-media thickness is increased not only in non-alcoholic fatty liver disease patients but also in alcoholic fatty liver patients. Digestion 2011; 84:149–155.
Leach NV, Dronca E, Vesa SC, Sampelean DP, Craciun EC, Lupsor M, et al. Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis. Eur J Intern Med 2014; 25:762–767.
Lee HJ, Lee CH, Kim S, Hwang SY, Hong HC, Choi HY, et al. Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by 18F-fluorodeoxyglucose positron emission tomography. Metab Clin Exp 2017; 67:72–79.
Li X, Shi HR, Wang Z, Chang L, Zhang MH, Dong XF. Arterial stiffness is increased in nondiabetic, nonhypertensive postmenopausal women with nonalcoholic fatty liver disease. J Hypertens 2017; 35:1226–1234.
Manco M, Bedogni G, Monti L, Morino G, Natali G, Nobili V. Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. Atherosclerosis 2010; 209:463–468.
Mikolasevic I, Milic S, Racki S, Zaputovic L, Stimac D, Radic M, et al. Nonalcoholic Fatty Liver Disease (NAFLD)-a new cardiovascular risk factor in peritoneal dialysis patients. Perit Dial Int 2016; 36:427–432.
Mikolasevic I, Racki S, Zaputovic L, Lukenda V, Sladoje-Martinovic B, Orlic L. Nonalcoholic fatty liver disease (NAFLD) and cardiovascular risk in renal transplant recipients. Kidney Blood Press Res 2014; 39:308–314.
Mishra S, Yadav D, Gupta M, Mishra H, Sharma P. A study of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. Indian J Clin Biochem 2013; 28:79–83.
Mohammadi A, Bazazi A, Ghasemi-Rad M. Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease. Int J Gen Med 2011; 4:717–722.
Mohammadi A, Sedani HH, Ghasemi-Rad M. Evaluation of carotid intima-media thickness and flow-mediated dilatation in middle-aged patients with nonalcoholic fatty liver disease. Vasc Health Risk Manag 2011; 7:661–665.
Mohammadzadeh A, Shahkarami V, Shakiba M, Sabetrasekh P, Mohammadzadeh M. Association of non-alcoholic fatty liver disease with increased carotid intima-media thickness considering other cardiovascular risk factors. Iran J Radiol 2019; 16:e14260.
Musa NI, Safwat E, Abdelhakam SM, Farid AM, Hetta WM. Noninvasive tool for the diagnosis of NAFLD in association with atherosclerotic cardiovascular risk. Egypt Liver J 2019; 9. doi:10.1186/s43066-019-0002-y.
doi: 10.1186/s43066-019-0002-y
Neri S, Signorelli SS, Scuderi R, Bruno M, Bertino G, Clementi A, et al. Carotid intima-media thickness and liver histology in hemodialysis patients with nonalcoholic Fatty liver disease. Int J Angiol 2011; 20:149–156.
Omar N, Koshy M, Hanafiah M, Hatta SFWM, Shah FZM, Johari B, et al. Relationships between severity of steatosis with glycemic control and carotid intima-media thickness among diabetic patients with ischemic heart disease. J Res Med Sci 2020; 25:64.
Oni E, Budoff MJ, Zeb I, Li D, Veledar E, Polak JF, et al. Nonalcoholic fatty liver disease is associated with arterial distensibility and carotid intima-media thickness: (from the multi-ethnic study of atherosclerosis). Am J Cardiol 2019; 124:534–538.
Ozturk K, Dogan T, Celikkanat S, Ozen A, Demirci H, Kurt O, et al. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2018; 30:411–417.
Ozturk K, Uygun A, Guler AK, Demirci H, Ozdemir C, Cakir M, et al. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. Atherosclerosis 2015; 240:380–386.
Petit JM, Guiu B, Terriat B, Loffroy R, Robin I, Petit V, et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 2009; 94:4103–4106.
Ramilli S, Pretolani S, Muscari A, Pacelli B, Arienti V. Carotid lesions in outpatients with nonalcoholic fatty liver disease. World J Gastroenterol 2009; 15:4770–4774.
Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010; 28:1699–1707.
Sanches PL, de Piano A, Campos RMS, Carnier J, de Mello MT, Elias N, et al. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy. J Clin Lipidol 2014; 8:265–272.
Sert A, Pirgon O, Aypar E, Yilmaz H, Odabas D. Relationship between left ventricular mass and carotid intima media thickness in obese adolescents with non-alcoholic fatty liver disease. J Pediatr Endocrinol Metab 2012; 25:927–934.
Silaghi CA, Silaghi H, Crăciun AE, Fărcaș A, Colosi HA, Cosma DT, et al. Age, abdominal obesity, and glycated hemoglobin are associated with carotid atherosclerosis in type 2 diabetes patients with nonalcoholic fatty liver disease. Med Ultrason 2015; 17:300–307.
Taharboucht S, Guermaz R, Brouri M, Chibane A. Subclinical atherosclerosis and arterial stiffness in nonalcoholic fatty liver disease: a case-control study in Algerian population. J Med Vasc 2021; 46:129–138.
Targher G, Bertolini L, Padovani R, Poli F, Scala L, Zenari L, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled Type 2 diabetic patients. J Endocrinol Invest 2006; 29:55–60.
Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007; 46:1126–1132.
Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29:1325–1330.
Tarnoki AD, Tarnoki DL, Bata P, Littvay L, Osztovits J, Jermendy G, et al. Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study. Liver Int 2012; 32:1287–1293.
Thakur ML, Sharma S, Kumar A, Bhatt SP, Luthra K, Guleria R, et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis 2012; 223:507–511.
Vanjiappan S, Hamide A, Ananthakrishnan R, Periyasamy SG, Mehalingam V. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease. Diabetes Metab Syndr 2018; 12:479–482.
Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens 2010; 23:1183–1189.
Xin Z, Zhu Y, Wang S, Liu S, Xu M, Wang T, et al. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score. Liver Int 2020; 40:806–814.
Yari FA, Shabani P, Karami S, Sarmadi N, Poustchi H, Bandegi AR. Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease. BMC Endocrine Disord 2021; 21:153.
Yoo HJ, Hwang SY, Choi J-H, Lee HJ, Chung HS, Seo J-A, et al. Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis. PLoS One 2017; 12:e0174717.
Zhang L, Guo K, Lu J, Zhao F, Yu H, Han J, et al. Nonalcoholic fatty liver disease is associated with increased carotid intima-media thickness in type 1 diabetic patients. Sci Rep 2016; 6:26805.